Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding

BURNABY, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering Coun

Related Keywords

Canada ,United Kingdom ,British ,Canadian ,Carole Ann Hupp ,Transbiotech Quebec ,Ted Steiner ,Hal Gunn ,Simon Sutcliffe ,Canadian Institutes Of Health Research ,Technology Center ,Division Of Infectious Diseases ,Natural Sciences ,Bc Cancer Agency ,Head Of Pharmaceutical Sciences At Transbiotech ,Community Innovation ,Humanities Research Council ,Engineering Council Of Canada ,Qu Biologics Inc ,British Columbia ,Biologics Inc ,Site Specific Immunomodulators ,Applied Research ,Engineering Council ,Social Sciences ,Canadian Institutes ,Shirin Kalyan ,Vice President ,Scientific Innovation ,Pharmaceutical Sciences ,Sarah Paris Robidas ,Chief Medical Officer ,Infectious Disease ,